Disruption of Iron Homeostasis to Induce Ferroptosis with Albumin-Encapsulated Pt(IV) Nanodrug for the Treatment of Non-Small Cell Lung Cancer

doi:10.1002/smll.202206688

科研成果详情

题名	Disruption of Iron Homeostasis to Induce Ferroptosis with Albumin-Encapsulated Pt(IV) Nanodrug for the Treatment of Non-Small Cell Lung Cancer
作者	Tian, Hui-Xiang 1,2,3; Mei, Jie 3,4,5,6,7; Cao, Lei 1,3; Song, Jianan 7; Rong, Dingchao 8; Fang, Man 1; Xu, Zhe 1; Chen, Juan 1; Tang, Jie 3,4,5,6; Xiao, Haihua 9; Liu, Zhaoqian 3,4,5,6; Wang, Peng-Yuan7; Yin, Ji-Ye 3,4,5,6; Li, Xiang-Ping 1,3
发表日期	2023-08-22
发表期刊	Small (Weinheim an der Bergstrasse, Germany) 影响因子和分区
语种	英语
原始文献类型	Journal Article
关键词	HSA@Pt(IV) ferroptosis ionome nanodrug platinum drug
其他关键词	CISPLATIN ; DELIVERY ; NANOPARTICLES ; OTOTOXICITY ; GENERATION ; THERAPY ; SYSTEM ; COPPER
摘要	Non-small cell lung cancer (NSCLC) is the most common pathological type of lung cancer , accounting for approximately 85% of lung cancers. For more than 40 years, platinum (Pt)-based drugs are still one of the most widely used anticancer drugs even in the era of precision medicine and immunotherapy. However, the clinical limitations of Pt-based drugs, such as serious side effects and drug resistance, have not been well solved. This study constructs a new albumin-encapsulated Pt(IV) nanodrug (HSA@Pt(IV)) based on the Pt(IV) drug and nanodelivery system. The characterization of nanodrug and biological experiments demonstrate its excellent drug delivery and antitumor effects. The multi-omics analysis of the transcriptome and the ionome reveals that nanodrug can activate ferroptosis by affecting intracellular iron homeostasis in NSCLC. This study provides experimental evidence to suggest the potential of HSA@Pt(IV) as a nanodrug with clinical application.
资助项目	Health Commission of Hunan Province[202213014985];National Natural Science Foundation of China[82073943];Hunan Cancer Hospital Climb Plan[YF2020011];Zhejiang Provincial Natural Science Foundation of China[LZ23C070004]
出版者	WILEY-V C H VERLAG GMBH
ISSN	1613-6810
EISSN	1613-6829
卷号	19 期号:49
DOI	10.1002/smll.202206688
页数	13
WOS类目	Chemistry, Multidisciplinary ; Chemistry, Physical ; Nanoscience & Nanotechnology ; Materials Science, Multidisciplinary ; Physics, Applied ; Physics, Condensed Matter
WOS研究方向	Chemistry ; Science & Technology - Other Topics ; Materials Science ; Physics
WOS记录号	WOS:001051581900001
收录类别	PUBMED ; SCIE ; EI ; SCOPUS
在线发表日期	2023-08
EI入藏号	20233414604469
EI主题词	Diseases
EI分类号	461.2 Biological Materials and Tissue Engineering ; 461.6 Medicine and Pharmacology ; 545.1 Iron ; 547.1 Precious Metals ; 802.2 Chemical Reactions
URL	查看原文
PubMed ID	37606911
SCOPUSEID	2-s2.0-85168353159
自科自定义期刊分类	T3(B)类
通讯作者地址	[Li, Xiang-Ping]Department of Pharmacy,Xiangya Hospital,Central South University,Changsha,410008,China ; [Yin, Ji-Ye]National Clinical Research Center for Geriatric Disorders,Xiangya Hospital,Central South University,Changsha,410008,China ; [Wang, Peng-Yuan]Oujiang Laboratory,Key Laboratory of Alzheimer's Disease of Zhejiang Province,Institute of Aging,Wenzhou Medical University,Wenzhou,325000,China
Scopus学科分类	Biotechnology;Chemistry (all);Biomaterials;Materials Science (all);Engineering (miscellaneous)
TOP期刊	TOP期刊
引用统计
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/182477
专题	卓越中心_老年研究院
通讯作者	Wang, Peng-Yuan; Yin, Ji-Ye; Li, Xiang-Ping
作者单位	1.Department of Pharmacy,Xiangya Hospital,Central South University,Changsha,410008,China; 2.School of Bioscience and Bioengineering,South China University of Technology,Guangzhou,510006,China; 3.National Clinical Research Center for Geriatric Disorders,Xiangya Hospital,Central South University,Changsha,410008,China; 4.Department of Clinical Pharmacology,Xiangya Hospital,Central South University,Changsha,410008,China; 5.Institute of Clinical Pharmacology,Hunan Key Laboratory of Pharmacogenetics,Central South University,Changsha,410008,China; 6.Engineering Research Center of Applied Technology of Pharmacogenomics,Ministry of Education,110 Xiangya Road,Changsha,410008,China; 7.Oujiang Laboratory,Key Laboratory of Alzheimer's Disease of Zhejiang Province,Institute of Aging,Wenzhou Medical University,Wenzhou,325000,China; 8.Department of Orthopaedic Surgery,The Third Affiliated Hospital,Guangzhou Medical University,Guangzhou,510150,China; 9.Beijing National Laboratory for Molecular Sciences,State Key Laboratory of Polymer Physics and Polymer Chemistry,Institute of Chemistry,Chinese Academy of Sciences,Beijing,100190,China
通讯作者单位	卓越中心_老年研究院
推荐引用方式 GB/T 7714	Tian, Hui-Xiang,Mei, Jie,Cao, Lei,et al. Disruption of Iron Homeostasis to Induce Ferroptosis with Albumin-Encapsulated Pt(IV) Nanodrug for the Treatment of Non-Small Cell Lung Cancer[J]. Small (Weinheim an der Bergstrasse, Germany),2023,19(49).
APA	Tian, Hui-Xiang., Mei, Jie., Cao, Lei., Song, Jianan., Rong, Dingchao., ... & Li, Xiang-Ping. (2023). Disruption of Iron Homeostasis to Induce Ferroptosis with Albumin-Encapsulated Pt(IV) Nanodrug for the Treatment of Non-Small Cell Lung Cancer. Small (Weinheim an der Bergstrasse, Germany), 19(49).
MLA	Tian, Hui-Xiang,et al."Disruption of Iron Homeostasis to Induce Ferroptosis with Albumin-Encapsulated Pt(IV) Nanodrug for the Treatment of Non-Small Cell Lung Cancer".Small (Weinheim an der Bergstrasse, Germany) 19.49(2023).